Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Analytics Overview

13
Form 483s Issued
1
483s converted to WL
15
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
12 Apr 2024
Taenaka Kogyo Co., Ltd.
Drugs
02 Feb 2024
Eugia Pharma Specialities Limited
Drugs
04 Jan 2024
Charles River Laboratories, Inc.
Drugs
22 Dec 2023
Eugia US Manufacturing LLC
Drugs
10 Nov 2023
C&T Dream Co., Ltd.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Brandy N Lepage
3
0
Camerson E Moore
1
0
Chen Sun
1
0
Christopher R Czajka
1
0
Anastasia M Shields
1
0
TITLE/ COMPANY Issue Date Status Details
Ventilation systems, including equipment for control of air pressure, are not adequately designed and constructed to minimize risks of contamination.
Taenaka Kogyo Co., Ltd.
12 Apr 2024 Normal Justification: The HVAC system's adequacy directly impacts the ability to maintain critical pressure differentials to prevent contamination.
Excerpt: The heating, ventilation, and air conditioning (HVAC) system used to establish the specified differential pressure between the production suites and the neighboring outside environment are not sufficient.
View Details
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Eugia Pharma Specialities Limited
02 Feb 2024 Normal Justification: The observation indicated deficiencies in HVAC system validation, especially concerning air quality and particle control in aseptic environments.
Excerpt: Qualification of the HVAC system...did not demonstrate it can maintain appropriate air quality for aseptic filling...smoke studies have not evaluated if air flow...would allow air ingress...
View Details
Your firm failed to establish adequate written procedures for production and process controls
Charles River Laboratories, Inc.
04 Jan 2024 Normal Justification: The HVAC system's influence on cleanroom conditions directly impacts the maintenance of appropriate environmental standards necessary for drug production.
Excerpt: The cleanroom airflow and differential pressure was determined to be affected by HVAC system settings...a loose HEPA filter acoustic liner.
View Details
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed
Charles River Laboratories, Inc.
04 Jan 2024 Normal Justification: The observation explicitly mentions HVAC settings impacting cleanroom compliance, making this process type relevant.
Excerpt: The cleanroom airflow and differential pressure was determined to be affected by HVAC system settings.
View Details
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Charles River Laboratories, Inc.
04 Jan 2024 Normal Justification: Issues with cleanroom settings directly linked to HVAC system settings suggest a critical deficiency in HVAC management and integration.
Excerpt: The cleanroom airflow and differential pressure was determined to be affected by HVAC system settings...
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.